Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 20;139(21):2440–2450. doi: 10.1161/CIRCULATIONAHA.118.039360

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Subpopulation treatment effect pattern plot showing the treatment effect of selexipag vs placebo on morbidity/mortality (hazard ratio plus 95% CIs and 95% confidence bands) by NT-proBNP (N-terminal pro brain natriuretic peptide) level at baseline. The black line indicates the hazard ratio of each subpopulation, the dark blue dashed line indicates the 95% CI for each individual subpopulation. The light blue dashed line shows the 95% confidence bands, which define the confidence interval of the best-fit line and indicate with 95% certainty the bounds within which the true curve will fall. Vertical lines indicate the 300 ng/L and 1400 ng/L NT-proBNP thresholds. HR indicates hazard ratio.